Ascelia Pharma Provides Update on the Orviglance NDA

Дата публикации: 03-07-2026 20:07:47

July 3, 2026 -- Ascelia Pharma AB (publ) (ticker: ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA	0	13.35	22-06-2026
2	Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)	0	13.98	30-06-2026
3	Camurus Provides Regulatory Update on the US NDA for CAM2029 (Oclaiz™) in Acromegaly	0	13.28	10-06-2026
4	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel	0	13.9	30-07-2026
5	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma	0	16.87	26-06-2026
6	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	0	8.61	15-07-2026
7	Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma	0	12.59	10-07-2026
8	BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer	0	13.23	07-08-2026
9	Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease	0	17.79	21-07-2026
10	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	0	8.22	01-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.3. Источник: www.drugs.com.